AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Myriad Genetics and Mayo Clinic form collaboration to develop novel Alzheimer's drugs.
(From Chemical Business NewsBase - Press Release)
Myriad Genetics Inc and Mayo Clinic are collaborating on the development of novel Alzheimer's disease therapeutics based upon several drug candidates that have been discovered at Mayo Clinic. Myriad Genetics has received worldwide exclusive therapeutic rights to the drug candidates and to further drug discoveries that result from collaboration on compounds that lower the beta amyloid peptide, Abeta42. Myriad Genetics has also licensed a broad patent application from Mayo Clinic that relates to compounds that lower Abeta42. The licence agreement provides Myriad Genetics with rights to develop and market all of the …
-
- Myriad Genetics is exclusive licensee of New Mayo Clinic patent on Amyloid...
-
News wire article from: Asia Africa Intelligence Wire
June 29, 2005
700+ words
-
- Myriad Genetics' Alzheimer's disease drug candidate cuts production of key...
-
News wire article from: Asia Africa Intelligence Wire
August 5, 2003
700+ words
-
- Event Brief of Q1 2004 Myriad Genetics Earnings Conference Call - Final.
-
News wire article from: Fair Disclosure Wire
November 12, 2003
700+ words
-
- Event Brief of Q4 2003 Myriad Genetics Earnings Conference Call - Final.
-
News wire article from: Fair Disclosure Wire
August 26, 2003
700+ words
-
- Q1 2004 Myriad Genetics Earnings Conference Call - Final.
-
News wire article from: Fair Disclosure Wire
November 12, 2003
700+ words
